tiprankstipranks
Trending News
More News >
Advertisement

PINK - AI Analysis

Compare

Top Page

PINK

Simplify Health Care ETF (PINK)

Rating:64Neutral
Price Target:
$36.00
The Simplify Health Care ETF (PINK) has a balanced overall rating, reflecting a mix of strong and weaker holdings. United Therapeutics (UTHR) and CVS Health (CVS) stand out as key contributors, with their robust financial performance, strategic initiatives, and positive earnings outlooks driving the fund's strength. However, weaker holdings like PureCycle Technologies (PCT), which struggles with financial challenges and negative cash flows, may have held back the ETF's rating. A notable risk factor is the fund's exposure to companies facing valuation concerns and financial pressures, which could impact overall stability.
Positive Factors
Strong Sector Focus
The ETF is heavily weighted in the health care sector, which has shown resilience and steady growth over time.
Healthy Performance
The fund has delivered strong returns over the past three months and year-to-date, indicating solid momentum.
Reasonable Expense Ratio
The ETF's expense ratio is moderate, making it a cost-effective option compared to many actively managed funds.
Negative Factors
Over-Concentration in Health Care
Nearly 90% of the fund is allocated to the health care sector, which could expose investors to sector-specific risks.
Weak Performance from Key Holdings
Some top holdings, like UnitedHealth and Regeneron, have underperformed year-to-date, which may drag on overall returns.
Limited Geographic Diversification
With over 98% exposure to U.S. companies, the ETF lacks international diversification, increasing vulnerability to domestic market conditions.

PINK vs. SPDR S&P 500 ETF (SPY)

PINK Summary

The Simplify Health Care ETF (Ticker: PINK) is an investment fund focused on the health care sector, including companies in biotechnology, pharmaceuticals, medical devices, and health care services. It holds well-known companies like UnitedHealth and AbbVie, giving investors exposure to businesses driving innovation and growth in health care. This ETF may appeal to those looking for long-term growth opportunities in a vital and expanding industry. However, new investors should be aware that its performance is closely tied to the health care sector, which can be affected by regulatory changes or market fluctuations.
How much will it cost me?The Simplify Health Care ETF (PINK) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specific sector like health care, which requires more research and expertise. It’s designed to give investors targeted exposure to innovative health care companies.
What would affect this ETF?The Simplify Health Care ETF (PINK) could benefit from advancements in biotechnology and pharmaceuticals, as well as increased demand for health care services driven by aging populations and global health awareness. However, it may face challenges from regulatory changes, pricing pressures in the pharmaceutical industry, and potential economic downturns that could impact consumer spending on health care. Its strong U.S. focus and top holdings in companies like UnitedHealth and AbbVie position it well for growth but also expose it to risks tied to U.S. health care policies.

PINK Top 10 Holdings

The Simplify Health Care ETF (PINK) is heavily concentrated in the U.S. health care sector, with top holdings spanning pharmaceuticals, biotechnology, and medical devices. Mineralys Therapeutics is a rising star, delivering strong gains thanks to positive clinical trial results, while United Therapeutics and AbbVie are steady performers, benefiting from strategic initiatives and robust earnings. On the flip side, UnitedHealth is lagging due to financial pressures from increased medical costs, and Regeneron’s mixed performance is holding back momentum. Overall, the fund’s focus on innovation and health care demand positions it for long-term growth despite some bumps along the way.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
UnitedHealth6.33%$12.93M$321.81B-36.89%
73
Outperform
United Therapeutics5.89%$12.02M$20.59B17.73%
75
Outperform
Mineralys Therapeutics, Inc.5.35%$10.92M$3.11B195.14%
53
Neutral
AbbVie5.05%$10.30M$397.72B20.10%
64
Neutral
PureCycle Technologies4.66%$9.51M$2.19B-6.28%
38
Underperform
CVS Health4.14%$8.45M$102.23B42.93%
76
Outperform
Danaher4.02%$8.20M$151.17B-11.68%
75
Outperform
Regeneron4.00%$8.17M$68.61B-29.25%
79
Outperform
Amgen3.66%$7.47M$157.08B-7.53%
70
Outperform
Arcutis Biotherapeutics3.56%$7.27M$3.10B191.47%
59
Neutral

PINK Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
31.69
Positive
100DMA
30.67
Positive
200DMA
29.91
Positive
Market Momentum
MACD
0.48
Positive
RSI
61.80
Neutral
STOCH
75.44
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.93, equal to the 50-day MA of 31.69, and equal to the 200-day MA of 29.91, indicating a bullish trend. The MACD of 0.48 indicates Positive momentum. The RSI at 61.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PINK.

PINK Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$213.47M0.50%
64
Neutral
$973.38M0.18%
75
Outperform
$797.06M0.75%
69
Neutral
$183.00M0.75%
74
Outperform
$179.35M0.75%
67
Neutral
$140.73M0.68%
70
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PINK
Simplify Health Care ETF
33.33
1.09
3.38%
IETC
iShares Evolved US Technology ETF
PWRD
Tcw Transform Systems Etf
TDVI
FT Cboe Vest Technology Dividend Target Income ETF
RSHO
Tema American Reshoring ETF
IYRI
NEOS Real Estate High Income ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement